Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998


1 Disclosed Funding Rounds $3,711,777,966

24 Participating Investments $668,821,099

Pharmaceutical, Chemical, Health Care, Biotechnology

Bayer offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology.

Leverkusen, Nordrhein-Westfalen, Germany, Europe (DE)

Organizations in Leverkusen in Pharmaceutical,
Organizations in Leverkusen in Chemical,
Organizations in Leverkusen in Health Care,
Organizations in Leverkusen in Biotechnology,
Organizations in Nordrhein-Westfalen in Pharmaceutical,
Organizations in Nordrhein-Westfalen in Chemical,
Organizations in Nordrhein-Westfalen in Health Care,
Organizations in Nordrhein-Westfalen in Biotechnology,
Organizations in Germany in Pharmaceutical,
Organizations in Germany in Chemical,
Organizations in Germany in Health Care,
Organizations in Germany in Biotechnology,
Organizations in Europe in Pharmaceutical,
Organizations in Europe in Chemical,
Organizations in Europe in Health Care,
Organizations in Europe in Biotechnology

Investors in Leverkusen in Pharmaceutical,
Investors in Leverkusen in Chemical,
Investors in Leverkusen in Health Care,
Investors in Leverkusen in Biotechnology,
Investors in Nordrhein-Westfalen in Pharmaceutical,
Investors in Nordrhein-Westfalen in Chemical,
Investors in Nordrhein-Westfalen in Health Care,
Investors in Nordrhein-Westfalen in Biotechnology,
Investors in Germany in Pharmaceutical,
Investors in Germany in Chemical,
Investors in Germany in Health Care,
Investors in Germany in Biotechnology,
Investors in Europe in Pharmaceutical,
Investors in Europe in Chemical,
Investors in Europe in Health Care,
Investors in Europe in Biotechnology

European Union (EU) (0 Investors) (0 Startups)

Founded date 08, 1863

Founders Johann Friedrich Weskott, Friedrich Bayer

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Equity

Also known as Bayer Aktiengesellschaft

Company Type For Profit

Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

Bayer operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, cosmetics, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, cold and cough, foot care, and sun protection categories. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to veterinarians. Bayer has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments, and research collaboration agreements with Halogen and Kyoto University to identify new drug candidates for the treatment of pulmonary diseases. Bayer distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has a strategic research alliance with Kyoto University to jointly identify new drug targets for the treatment of pulmonary diseases, such as idiopathic pulmonary fibrosis. Friedrich Bayer and Johann Friedrich Weskott founded Bayer on August 1, 1863. It has its headquarters in Leverkusen in Germany.

Date Round Raised Lead
April, 17, 2018 Post-IPO Equity $3,711,777,966 Temasek Holdings

Bayer Participated In the Following Investment Rounds (24)

Organization Name Lead? Round Partners Participating Raise Date
Elly No Venture - Series Unknown ------- Undisclosed November, 17, 2020
OneDrop Yes Series C ------- $34,700,000 August, 24, 2020
Oerth Bio No Corporate Round ------- $55,000,000 February, 27, 2020
Okko Health Yes Pre-Seed ------- $381,658 January, 01, 2020
Immunitas Therapeutics Yes Series A ------- $39,000,000 November, 22, 2019
Litesprite Yes Seed ------- Undisclosed November, 10, 2019
EGenesis No Series B ------- $100,000,000 November, 07, 2019
Huma Yes Series B ------- $25,000,000 November, 05, 2019
BioLum Sciences No Corporate Round ------- Undisclosed October, 10, 2019
Upside Health Yes Seed ------- $200,000 October, 10, 2019
OneDrop Yes Series B ------- $40,000,000 September, 17, 2019
Metagenomi Yes Series A ------- $26,373,182 August, 16, 2019
BioSTL Yes Grant ------- $1,500,000 August, 06, 2019
aparito Yes Seed ------- $1,321,099 March, 01, 2019
S-There Technologies No Pre-Seed ------- Undisclosed December, 01, 2018
The Muny Yes Venture - Series Unknown ------- $5,000,000 November, 14, 2018
Covercress Yes Venture - Series Unknown ------- $2,000,000 November, 13, 2018
Bayer–Gingko Fertilizer Partnership No Series A ------- $100,000,000 March, 20, 2018
Sky Labs No Seed ------- Undisclosed October, 03, 2017
Joyn Bio No Series A ------- $100,000,000 September, 14, 2017
Sky Labs No Seed ------- Undisclosed June, 01, 2017
Boragen No Series A ------- $10,000,000 March, 02, 2017
BlueRock Therapeutics Yes Series A ------- $225,000,000 December, 12, 2016
yet2.com Yes Venture - Series Unknown ------- $20,000,000 January, 06, 2000

Bayer Investors (1)

Investor Lead? Round Participating Raise Date Partners
Temasek Holdings Yes Post-IPO Equity $3,711,777,966 April, 17, 2018 -------